Marinus Pharmaceuticals (MRNS) & CoLucid Pharmaceuticals (NASDAQ:CLCD) Financial Comparison

CoLucid Pharmaceuticals (NASDAQ: CLCD) and Marinus Pharmaceuticals (NASDAQ:MRNS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

Analyst Recommendations

This is a summary of current ratings and recommmendations for CoLucid Pharmaceuticals and Marinus Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CoLucid Pharmaceuticals 0 0 0 0 N/A
Marinus Pharmaceuticals 0 0 3 0 3.00

Marinus Pharmaceuticals has a consensus price target of $20.67, suggesting a potential upside of 232.26%. Given Marinus Pharmaceuticals’ higher possible upside, analysts plainly believe Marinus Pharmaceuticals is more favorable than CoLucid Pharmaceuticals.

Profitability

This table compares CoLucid Pharmaceuticals and Marinus Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CoLucid Pharmaceuticals N/A -83.51% -70.62%
Marinus Pharmaceuticals N/A -67.76% -55.65%

Earnings and Valuation

This table compares CoLucid Pharmaceuticals and Marinus Pharmaceuticals’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CoLucid Pharmaceuticals N/A N/A N/A ($3.43) -13.57
Marinus Pharmaceuticals N/A N/A -$28.64 million ($0.93) -6.69

CoLucid Pharmaceuticals is trading at a lower price-to-earnings ratio than Marinus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

64.2% of CoLucid Pharmaceuticals shares are owned by institutional investors. Comparatively, 52.6% of Marinus Pharmaceuticals shares are owned by institutional investors. 13.7% of CoLucid Pharmaceuticals shares are owned by insiders. Comparatively, 6.4% of Marinus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Marinus Pharmaceuticals beats CoLucid Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

About CoLucid Pharmaceuticals

CoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company’s lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain. It is developing IV lasmiditan for the acute treatment of headache pain associated with migraine in adults, to be used in emergency rooms and urgent care settings. The Company is conducting its Phase III randomized, double-blind, placebo-controlled clinical trial of lasmiditan.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.

Receive News & Ratings for CoLucid Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CoLucid Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply